$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023086255 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$1.240M	$901.9K	$2.310M
YoY Change	163.99%	181.14%	348.75%
Cost Of Revenue	$745.6K	$787.7K	$740.0K
YoY Change	120.18%	235.14%	179.2%
Gross Profit	$324.1K	$21.24K	$1.570M
YoY Change	147.13%	-104.33%	528.7%
Gross Profit Margin	26.14%	2.36%	67.97%
Selling, General & Admin	$1.364M	$1.300M	$1.410M
YoY Change	-6.89%	-16.69%	-19.08%
% of Gross Profit	420.79%	6119.95%	89.81%
Research & Development	$609.8K	$1.292M	$620.0K
YoY Change	-28.37%	-6.28%	-58.69%
% of Gross Profit	188.12%	6082.73%	39.49%
Depreciation & Amortization	$14.24K	$54.83K	$50.00K
YoY Change	-70.96%	11.79%	-7.39%
% of Gross Profit	4.39%	258.13%	3.18%
Operating Expenses	$1.969M	$2.694M	$2.090M
YoY Change	-16.75%	-9.84%	-36.61%
Operating Profit	-$1.645M	-$2.537M	-$520.0K
YoY Change	-21.71%	-27.73%	-82.94%
Interest Expense	$226.7K	$90.00K	$180.0K
YoY Change	66.63%	-471.9%	-603.64%
% of Operating Profit
Other Income/Expense, Net		$136.0K
YoY Change		106.79%
Pretax Income	-$1.478M	-$2.537M	-$340.0K
YoY Change	-29.55%	-27.59%	-95.68%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$1.478M	-$2.500M	-$340.0K
YoY Change	-29.65%	-28.78%	-95.68%
Net Earnings / Revenue	-119.19%	-277.2%	-14.72%
Basic Earnings Per Share	-$0.19	-$0.76
Diluted Earnings Per Share	-$0.19	-$0.76	-$0.10
COMMON SHARES
Basic Shares Outstanding	5.255M shares	3.328M shares	3.328M shares
Diluted Shares Outstanding	7.973M shares	3.328M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.579M	$6.780M	$8.960M
YoY Change	-16.67%	-27.82%	44.01%
Cash & Equivalents	$9.535M	$6.738M	$8.913M
Short-Term Investments	$44.46K	$40.00K	$40.00K
Other Short-Term Assets	$1.113M	$220.0K	$500.0K
YoY Change	34.59%	-38.32%	-37.28%
Inventory	$744.8K	$1.133M	$1.616M
Prepaid Expenses
Receivables	$372.9K	$165.9K	$260.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.81M	$8.295M	$11.33M
YoY Change	-15.75%	-28.14%	18.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.481M	$615.1K	$723.4K
YoY Change	110.41%	-23.35%	-20.0%
Goodwill
YoY Change
Intangibles	$1.864M		$1.946M
YoY Change	-8.02%		-7.71%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$101.8K	$104.9K
YoY Change	-41.56%	-40.52%	-40.61%
Total Long-Term Assets	$3.445M	$2.622M	$2.775M
YoY Change	18.73%	-13.79%	-13.02%
TOTAL ASSETS
Total Short-Term Assets	$11.81M	$8.295M	$11.33M
Total Long-Term Assets	$3.445M	$2.622M	$2.775M
Total Assets	$15.26M	$10.92M	$14.11M
YoY Change	-9.84%	-25.14%	10.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$306.5K	$380.0K	$540.0K
YoY Change	-60.24%	-65.34%	-53.69%
Accrued Expenses	$100.4K	$960.0K	$1.440M
YoY Change	-93.78%	-42.52%	-12.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.680M	$1.339M	$2.001M
YoY Change	-30.0%	-59.19%	-39.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$802.8K	$0.00	$20.00K
YoY Change	336.53%	-100.0%	-94.87%
Total Long-Term Liabilities	$802.8K	$0.00	$20.00K
YoY Change	336.53%	-100.0%	-94.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.680M	$1.339M	$2.001M
Total Long-Term Liabilities	$802.8K	$0.00	$20.00K
Total Liabilities	$2.483M	$1.339M	$2.017M
YoY Change	-3.92%	-62.55%	-45.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.4M	-$103.9M	-$101.4M
YoY Change	6.4%	7.15%	8.5%
Common Stock	$79.94M	$113.4M	$77.62M
YoY Change	6.78%	56.03%	9.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.77M	$9.578M	$12.09M
YoY Change
Total Liabilities & Shareholders Equity	$15.26M	$10.92M	$14.11M
YoY Change	-9.84%	-25.14%	10.31%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.478M	-$2.500M	-$340.0K
YoY Change	-29.65%	-28.78%	-95.68%
Depreciation, Depletion And Amortization	$14.24K	$54.83K	$50.00K
YoY Change	-70.96%	11.79%	-7.39%
Cash From Operating Activities	-$1.852M	-$2.174M	-$650.0K
YoY Change	-31.73%	-3.61%	-83.94%
INVESTING ACTIVITIES
Capital Expenditures	$9.290K		$160.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$130.0K
YoY Change	-100.0%		-117.92%
Cash From Investing Activities	-$9.290K		-$30.00K
YoY Change	-98.14%		-95.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.654M		0.000
YoY Change	-12.44%		-100.0%
NET CHANGE
Cash From Operating Activities	-1.852M	-$2.174M	-650.0K
Cash From Investing Activities	-9.290K		-30.00K
Cash From Financing Activities	4.654M		0.000
Net Change In Cash	2.792M	-$2.174M	-680.0K
YoY Change	32.84%	-168.51%	-344.12%
FREE CASH FLOW
Cash From Operating Activities	-$1.852M	-$2.174M	-$650.0K
Capital Expenditures	$9.290K		$160.0K
Free Cash Flow	-$1.862M		-$810.0K
YoY Change	-31.38%		-79.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3328191	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	001-39685
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 310 - 815 W. Hastings Street
CY2023Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
CY2023Q3	dei	Entity Address Country EntityAddressCountry	CA
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 1B4
CY2023Q3	dei	City Area Code CityAreaCode	(604)
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	669-7207
CY2023Q3	dei	Security12b Title Security12bTitle	Common Shares, no par value
CY2023Q3	dei	Trading Symbol TradingSymbol	INM
CY2023Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5254970	shares
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6738304	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	42942	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	44422	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165850	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	260399	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1133097	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	215015	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	498033	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8295208	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11331727	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	615055	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1905286	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1946279	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	101790	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104908	usd
CY2023Q3	us-gaap	Assets Assets	10917339	usd
CY2023Q2	us-gaap	Assets Assets	14106340	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1046251	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	292998	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2023Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16171	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1339249	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2000619	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1339249	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2016613	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35766306	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35741115	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103937037	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400209	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9578090	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10917339	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14106340	usd
CY2023Q3	us-gaap	Revenues Revenues	901862	usd
CY2022Q3	us-gaap	Revenues Revenues	320788	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	787690	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	235034	usd
CY2023Q3	inm	Inventory Writedown InventoryWritedown	92930	usd
CY2022Q3	inm	Inventory Writedown InventoryWritedown	576772	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	21242	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-491018	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1292093	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1378653	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1298731	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1560477	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54832	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	49048	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-48457	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-96791	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2694113	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3084969	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	136043	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	72587	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2536828	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3503400	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6800	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.06
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3328191	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	865619	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	25191	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9578090	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2022Q3	inm	Registered Direct And Private Placement RegisteredDirectAndPrivatePlacement	5999946	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1129343	usd
CY2022Q3	inm	Adjustments To Additional Paid In Agents Investment Options AdjustmentsToAdditionalPaidInAgentsInvestmentOptions	451897	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	419	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	116680	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11007940	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	54832	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49048	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	25191	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	116680	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94532	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	99460	usd
CY2023Q3	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	538	usd
CY2022Q3	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	120	usd
CY2023Q3	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2018	usd
CY2022Q3	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2796	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-390329	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-135559	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-283018	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-440560	usd
CY2023Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3118	usd
CY2022Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-94549	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-72858	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-562484	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-159260	usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	16171	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	15700	usd
CY2023Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	98709	usd
CY2022Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	100903	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2174213	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2255543	usd
CY2023Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	21317	usd
CY2023Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	21317	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000365	usd
CY2022Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	571261	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5429104	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2174213	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3173561	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6738304	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9350427	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6800	usd
CY2022Q3	inm	Preferred Investment Options To Its Placement Agent PreferredInvestmentOptionsToItsPlacementAgent	547441	usd
CY2023Q3	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Through September 30, 2023, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $2.5 million and $3.5 million for the three months ended September 30, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of approximately $103.9 million as at September 30, 2023. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash, cash equivalents and short-term investments of $6.8 million as of September 30, 2023, combined with the approximate $4.7 million of net proceeds from a private placement which closed on October 26, 2023 (see Note 13), will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of calendar 2024, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the health and wellness sector as well as the level and timing of the Company’s operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>COVID-19 Impacts</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s consolidated financial statements as of and for the three months ended September 30, 2023, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</p>
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2500000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3500000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103900000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	6800000	usd
CY2023Q4	inm	Net Proceeds NetProceeds	4700000	usd
CY2023Q3	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the three months ended September 30, 2023, we adopted a change in presentation on our consolidated statements of operations loss in order to include foreign exchange loss in operating expenses. Prior periods have been revised to reflect this change in the presentation.</p>
CY2023Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The preparation of financial statements in compliance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and warrant valuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Actual results could differ from those estimates.</p>
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	186750	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	93820	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2023Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation (CDIC) insurable limits. The Company has not experienced any losses related to these balances. The uninsured cash balance as of September 30, 2023, was $2.9 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s customers are primarily concentrated in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify; text-indent: 18pt">As of September 30, 2023, the Company had three customers with an accounts receivable balance representing 35%, 22% and 11% of total accounts receivable, respectively. As of June 30, 2023, we had three customers with an accounts receivable balance representing 41%, 30% and 15% of total accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the three months ended September 30, 2023, the Company had three customers that accounted for 34%, 20% and 11% of revenue, respectively. For the three months ended September 30, 2022, the Company had three customers that accounted for 43%, 22% and 12% of revenue, respectively.</p>
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2900000	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3618662	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1573684	shares
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	85655	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	514113	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	838705	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893506	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1133097	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2023Q3	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings	186750	usd
CY2023Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings	93820	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1648747	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1648747	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1033692	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925321	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	615055	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	13839	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	8055	usd
CY2023Q3	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	94532	usd
CY2022Q3	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	90244	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1022134	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	981141	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1905286	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1946279	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2023Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2023Q3	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	117943	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	158935	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	158935	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	158935	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	158935	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1151603	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1905286	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	379866	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	544179	usd
CY2023Q3	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	286684	usd
CY2023Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	164587	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	279556	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	542305	usd
CY2023Q3	inm	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	100145	usd
CY2023Q2	inm	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	357664	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1046251	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102642	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.28
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	509	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	495.98
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102133	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.52
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	51403	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	51.53
CY2023Q3	inm	Share Based Compensation Arrangements By Share Based Payment Award Options Number Unvested ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberUnvested	50730	shares
CY2023Q3	inm	Weighted Average Exercise Price Unvested WeightedAverageExercisePriceUnvested	5.21
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25191	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	116681	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	42297	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P0Y9M7D
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	297759	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4761	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	292998	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	292998	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1095104	usd
CY2023Q3	us-gaap	Revenues Revenues	901862	usd
CY2022Q3	us-gaap	Revenues Revenues	320788	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	787690	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	235034	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	92930	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2694113	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3084969	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	136043	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65787	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2536828	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3510200	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6738304	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9350427	usd
CY2023Q3	inm	Cost Of Services Directs Materials CostOfServicesDirectsMaterials	2200000	usd
CY2023Q3	us-gaap	Cost Direct Material CostDirectMaterial	300000	usd
CY2023Q3	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	42942	usd
CY2023Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44422	usd
CY2023Q3	inm	Warrants To Purchase WarrantsToPurchase	700	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	700	shares
CY2023Q3	inm	Agreement Amount AgreementAmount	300000	usd
CY2023Q3	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	19814	usd
CY2022Q3	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	67092	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q2	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	865619	shares
CY2022Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q3	inm	Preferred Investment Options To Its Placement Agent PreferredInvestmentOptionsToItsPlacementAgent		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
inm-20230930_cal.xml	Edgar Link	unprocessable
inm-20230930_lab.xml	Edgar Link	unprocessable
inm-20230930_def.xml	Edgar Link	unprocessable
inm-20230930_pre.xml	Edgar Link	unprocessable
0001213900-23-086255-index-headers.html	Edgar Link	pending
0001213900-23-086255-index.html	Edgar Link	pending
0001213900-23-086255.txt	Edgar Link	pending
0001213900-23-086255-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_inmedpharma.htm	Edgar Link	pending
f10q0923ex31-2_inmedpharma.htm	Edgar Link	pending
f10q0923ex32-1_inmedpharma.htm	Edgar Link	pending
f10q0923ex32-2_inmedpharma.htm	Edgar Link	pending
f10q0923ex4-13_inmedpharma.htm	Edgar Link	pending
f10q0923_inmedpharma.htm	Edgar Link	pending
f10q0923_inmedpharma_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
inm-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2023 Q4 Form 10-Q Financial Statement

#000121390023086255 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2023 Q4 Form 10-Q Financial Statement

#000121390023086255 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm